AGE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 mar 2024 @ 20:59):

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States...

Stats
Dagens volum	3 681.00
Gjennomsnittsvolum	3 980.00
Markedsverdi	27.76M
EPS	$0 ( 2024-03-29 )
Neste inntjeningsdato	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-08	Mintz Steven	Sell	0	Common Stock, $0.0001 par value
2024-01-08	Mintz Steven	Sell	63 756	Option to Purchase Common Stock
2023-08-09	Renondin Jean-christophe	Sell	25 821	Option to Purchase Common Stock
2023-04-25	Juvenescence Ltd	Buy	756 429	Warrant to Purchase Common Stock
2023-03-14	Juvenescence Ltd	Sell	16 447 500	Common Stock

INSIDER POWER
-63.36
Last 97 transactions
Buy: 22 648 571 \| Sell: 17 037 050

AgeX Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

AgeX Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$142 000
Bruttogevinst:	$-29 000.00 (-20.42 %)
EPS:	$-13.72

FY	2023
Omsetning:	$142 000
Bruttogevinst:	$-29 000.00 (-20.42 %)
EPS:	$-13.72

FY	2022
Omsetning:	$34 000.00
Bruttogevinst:	$21 000.00 (61.76 %)
EPS:	$-9.89

FY	2021
Omsetning:	$144 000
Bruttogevinst:	$125 000 (86.81 %)
EPS:	$-0.230

Financial Reports:

No articles found.

AgeX Therapeutics Inc

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.